What guidance did Amylyx's management provide for the next earnings period?

What is the market's earnings forecast for Amylyx next quarter?

What is the revenue and EPS growth rate for Amylyx year over year?

What were the key takeaways from Amylyx's earnings call?

What is Amylyx's gross profit margin?

What does Amylyx do and what are its main business segments?

What factors drove the changes in Amylyx's revenue and profit?

What were the key takeaways from Amylyx’s earnings call?

- **Avexitide Trial Milestone**: LUCIDITY recruitment complete, targeting 2027 launch with 160,000 U.S. PBH patients estimated.
- **Financial Strength**: $317 million cash runway into 2028, 8% YoY expense decline.
- **Pipeline Expansion**: AMX0318 nominated for long-acting GLP-1 antagonist, IND filing in 2027.
- **Market Validation**: Clinician and patient feedback confirm PBH as severe, unmet need.

**Management Opening Remarks**
- Lindsey Allen introduced executives and outlined the call's focus on 2025 achievements and future plans.

**CEO Commentary**
- **Avexitide Progress**: Pivotal Phase III LUCIDITY trial recruitment completed, with final participants dosed in Q1 2026. Trial powered for 35% effect vs. placebo, no prior placebo response in Phase II.
- **Commercial Readiness**: Preparing for 2027 launch with market research estimating 160,000 U.S. PBH patients.
- **Pipeline Expansion**: AMX0318 nominated as a long-acting GLP-1 antagonist for PBH, with IND filing targeted for 2027.
- **ALS Progress**: AMX0114 Phase I trial progressing, Cohort 2 enrollment ongoing.

**CFO Commentary**
- **Financial Position**: $317 million cash at Q4 2025, runway into 2028.
- **Expense Management**: 8% YoY decline in operating expenses, driven by reduced AMX0035 spending.
- **Milestone Payment**: $4 million to Gubra for AMX0318 nomination, reflected in Q1 2026 R&D expenses.

**Q&A Highlights**
- **Trial Design**: LUCIDITY powered to replicate Phase II results, with 160,000 patient estimate validated through claims data.
- **Competitive Landscape**: Acarbose poorly tolerated, reinforcing avexitide's potential as first FDA-approved PBH treatment.
- **Safety**: Avexitide showed no significant immunogenicity or injection site reactions in prior trials.

Amylyx Pharmaceuticals, Inc.(AMLX)-20260303-2025 Q4 Earnings call transcript

- **LUCIDITY Trial Update**: Enrollment completion now expected in Q1 2026, with top-line data in Q3 2026. Avexitide remains on track for a 2027 launch pending FDA approval.
- **Financial Strength**: $344 million cash position supports a 2028 runway. Operating expenses down 53% YoY, driven by reduced pipeline spending.
- **Pipeline Progress**: Gubra collaboration for a long-acting GLP-1 antagonist nearing candidate nomination. AMX0035 pivotal trial initiation in H2 2026 pending FDA alignment.
- **Market Focus**: 160,000 PBH patients in the U.S., with unmet need driving avexitide's development and commercial readiness.

**【Management Opening Remarks】**
- Lindsey Allen provided an overview of the company's focus on avexitide for post-bariatric hypoglycemia (PBH) and the LUCIDITY Phase III trial. The call emphasized the unmet need in PBH and the company's strategic focus on avexitide's development and commercial readiness.

**【CEO Commentary】**
- Justin Klee highlighted the LUCIDITY trial's enrollment update, noting a steady rate and revised completion timeline to Q1 2026, with top-line data expected in Q3 2026. He emphasized avexitide's potential as the first FDA-approved therapy for PBH and the company's preparation for a 2027 launch pending FDA approval. Klee also discussed the pipeline, including the Gubra collaboration for a long-acting GLP-1 antagonist, with a decision on a development candidate expected in the next few months.

**【CFO Commentary】**
- James Frates reported a strong cash position of $344 million at quarter-end, supporting a 2028 cash runway. He noted a 53% year-over-year decline in operating expenses, driven by reduced spending on AMX0035 and AMX0114, and highlighted the company's focus on avexitide's clinical execution and commercial preparation.

**【Q&A Highlights】**
- Enrollment dynamics: Justin Klee and Joshua Cohen addressed the steady enrollment rate, revised timeline, and site activation challenges. Josh Cohen emphasized the importance of dietary adherence and CGM monitoring in trial execution. Questions on the addressable market for PBH (160,000 individuals) and pipeline updates on AMX0114 and AMX0035 were also key topics.

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript

- **Avexitide Momentum**: Phase III LUCIDITY on track for H1 2026 readout; 64% event reduction in Phase II. ~167k U.S. PBH patients identified.
- **Pipeline Progress**: PSP Phase IIb data Q3; ALS Fast Track designation. GLP-1 collaboration with Gubra shows early promise.
- **Financial Strength**: $180.8M cash runway through 2026. Q2 expenses down 43% YoY, with R&D investment in lead programs.
- **Commercial Readiness**: 2027 launch prep underway; endo community engagement strong.


**【CEO Opening Remarks】**
- **Avexitide Progress**: Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH) dosed first participant in April, with recruitment expected to complete by year-end. Avexitide is on track for a 2027 launch if approved.
- **GLP-1 Collaboration**: Partnering with Gubra to develop long-acting GLP-1 receptor antagonists, with early molecules showing promising potency and half-life.
- **Pipeline Updates**: AMX0035 Phase IIb data in PSP expected Q3; AMX0114 Phase I data in ALS expected this year. Fast Track designation granted for AMX0114.

**【CMO Clinical Updates】**
- **Avexitide Efficacy**: Phase II data showed 64% reduction in Level 2/3 hypoglycemic events (p=0.003), with 50% of patients experiencing no events. Phase III powered to detect ≥35% reduction vs. placebo with 90% power.
- **Market Size**: ~167,000 U.S. patients with medically important PBH (119k Roux-en-Y, 48k sleeve gastrectomy). Prevalence model highlights unmet need.
- **PSP Program**: Phase IIb/III ORION trial data expected Q3; 20% slowing of PSPRS progression set as go/no-go threshold.

**【CFO Financial Commentary】**
- **Cash Position**: $180.8M as of Q2, supporting clinical milestones and 2026 cash runway.
- **Q2 Expenses**: Total $42.9M (-43% YoY). R&D $27.2M (+16%) due to Avexitide and PSP spending; SG&A $15.6M (-28%) from cost reductions.
- **Key Milestones**: LUCIDITY top line (H1 2026), PSP Phase IIb data (Q3 2025), ALS early cohort data (2025).

**【Q&A Highlights】**
- **Market Education**: Endo 2025 highlighted PBH as underserved; ICD-10 code efforts ongoing. Endocrinologists report high patient motivation for Avexitide.
- **Enrollment Confidence**: 75-patient LUCIDITY trial on track for H1 2026 readout. Sites report strong patient engagement and compliance (>99% in prior trials).
- **PSP Decision Criteria**: 20% PSPRS slowing threshold; secondary endpoints include biomarkers and imaging. All participants will have 24-week data, with longer-term data available for subset.
- **Avexitide Compliance**: Daily injection well-tolerated; efficacy outweighs minor inconvenience. Phase II compliance rates near 100%.


Amylyx Pharmaceuticals (AMLX)-7 Aug 25-2025 Q2 Earnings call transcript

- **Avexitide Phase III Launched**: First participant dosed in pivotal trial for PBH, with potential 2027 launch if approved. 
- **$65.5M Financing**: Extends cash runway to end-2026, supporting 4 clinical trials. 
- **New ALS Trial Initiated**: AMX0114 Phase I trial begins targeting Calpain-2 for axonal degeneration. 
- **Upcoming Data Milestones**: Week 48 Wolfram data (ENDO 2025), PSP Phase IIb results (Q3), and Avexitide top-line readout (H1 2026).

**【CEO Summary Section】**
- **Avexitide Phase III LUCIDITY Trial**: Dosed first participant in pivotal Phase III trial for post-bariatric hypoglycemia (PBH), targeting 75 patients. Anticipates top-line data in H1 2026 and potential launch in 2027 if approved. 
- **AMX0035 in Wolfram Syndrome**: Week 48 data from Phase II HELIOS trial to be presented at ENDO 2025, showing sustained improvement in neurodegenerative biomarkers. Phase III design discussions with FDA ongoing. 
- **AMX0035 in PSP**: Phase IIb ORION trial enrollment complete (139 participants), with top-line data expected Q3 2025. 
- **AMX0114 in ALS**: Dosed first participant in Phase I LUMINA trial, evaluating Calpain-2 knockdown for axonal degeneration. Early cohort data expected later this year. 
- **Financial Update**: Raised $65.5M in Q1, extending cash runway to end-2026. Total cash of $204.1M as of Q1 2025.

**【CFO Financial Commentary】**
- **Cash Position**: $204.1M (including $65.5M from Q1 equity offering). Sufficient funds to support clinical milestones through 2026. 
- **Operating Expenses**: Total Q1 2025 expenses $37.8M (-82% YoY). R&D: $22.1M (-39% YoY); SG&A: $15.7M (-73% YoY). Reduction driven by discontinuation of RELIVRIO/ALBRIOZA sales and lower personnel costs. 
- **One-Time Costs**: $1.4M Q1 2025 for product rebates/settlements; $3.1M remaining obligations through 2025.

**【Q&A Key Highlights】**
- **Avexitide Patient Education**: Targeting 160,000 U.S. PBH patients (8% of bariatric surgery patients). Education campaign needed due to lack of awareness and no approved treatments. 
- **PSP Trial Efficacy**: Phase IIb powered to detect 30% effect on PSP Rating Scale. Clinically meaningful difference estimated at 6-10 points over 6 months. 
- **PBH Prevalence**: 160,000 symptomatic patients in U.S., with ~300,000 new bariatric surgeries annually. 1-3 years post-surgery onset, chronic progression. 
- **Wolfram Trial Design**: Week 48 data will inform Phase III endpoints, including neurodegenerative biomarkers and functional assessments. No prior therapies exist. 
- **Avexitide Safety**: Well-tolerated in 5 clinical trials, with no weight gain or hyperglycemia. Preclinical studies show no adverse effects at high doses.

Amylyx Pharmaceuticals (AMLX)-8 May 25-2025 Q1 Earnings call transcript

- **Avexitide Phase 3 Launch**: Pivotal trial for PBH begins Q2 2025, targeting 160,000 U.S. patients with no approved treatments.
- **$65.5M Financing**: Strengthens cash runway to 2026 for commercial prep and clinical execution.
- **Key Milestones**: PSP interim data Q3 2025, Wolfram Week 48 results, and ALS Phase 1 readouts.
- **Cost Efficiency**: Q4 2024 expenses down 62% YoY, with $176.5M cash on hand.
- **GLP-1 Antagonist Potential**: Expanding pipeline beyond PBH with long-acting candidate in development.

**【CEO Summary Section】**
- Launched pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia (PBH), with first dosing expected in Q2 2025 and top-line data in H1 2026.
- Secured $65.5M financing to support commercial preparation for avexitide and extend cash runway to end-2026.
- Focused on 12-15 month execution window with key milestones: avexitide Phase 3 readout, PSP interim analysis, Wolfram syndrome Week 48 data, and ALS Phase 1 results.
- Estimated 160,000 PBH patients in the U.S., with persistent need due to chronic nature of condition and ongoing bariatric surgery demand.

**【CFO Financial Commentary】**
- Q4 2024 total operating expenses: $39.9M (down 62% YoY), driven by reduced R&D ($22.9M vs. $44.9M) and SG&A ($17.1M vs. $52.2M).
- Ended 2024 with $176.5M cash (excluding January 2025 offering proceeds), supporting clinical and commercial activities through 2026.
- Remaining obligations from prior programs: ~$7.8M to be settled in 2025.

**【CMO Clinical Update】**
- Avexitide Phase 3 LUCIDITY trial: 75 participants, 16-week study evaluating reduction in Level 2/3 hypoglycemic events.
- Prior Phase 2b data showed 53% reduction in Level 2 events (p=0.004) and 66% reduction in Level 3 events (p=0.0003) at 90mg dose.
- Favorable safety profile with consistent dose-dependent effects across five clinical trials.

**【Q&A Key Points】**
- **PBH Market Dynamics**: 160,000 U.S. patients, growing due to persistent bariatric surgery demand and chronic nature of PBH.
- **Avexitide Long-Acting Pipeline**: Collaborating with Gubra to develop GLP-1 receptor antagonist for potential broader applications.
- **PSP Trial Design**: Using both 10-item and 28-item PSP rating scales, with expectations of consistent results across regions.
- **Wolfram Syndrome Week 48 Data**: Focused on C-peptide response, visual acuity, and beta cell function improvements.
- **Pricing Strategy**: Orphan drug pricing framework, with efficacy-driven value for severe hypoglycemia management.

Actual	-4.23	-0.93	-0.93	-0.92	-0.65	0.02	0.31	0.3	0.07	-1.75	-1.07	-1.07	-0.55	-0.42	-0.46	-0.37	-0.3
Forecast	-6.935	-0.6867	-0.8725	-0.9716	-0.8196	-0.2406	0.19	0.4375	0.2278	-0.004	-0.73	-0.704	-0.52	-0.475	-0.4444	-0.4358	-0.3487
Surprise	+39.01%	-35.43%	-6.59%	+5.31%	+20.69%	+108.31%	+63.16%	-31.43%	-69.27%	-43650.00%	-46.58%	-51.99%	-5.77%	+11.58%	-3.51%	+15.10%	+13.97%

Actual	0	0	0	345.00K	21.89M	71.43M	98.20M	102.69M	108.45M	88.60M	-1.02M	416.00K	-665.00K	0	0	0	0
Forecast	338.33K	83.33K	125.00K	83.33K	4.72M	58.99M	92.21M	113.66M	106.96M	98.35M	10.66M	0	0	0	0	52.00K	-83.20K
Surprise	-100.00%	-100.00%	-100.00%	+314.00%	+363.26%	+21.09%	+6.49%	-9.65%	+1.39%	-9.91%	-109.59%	0.00%	0.00%	0.00%	0.00%	-100.00%	+100.00%

AMLX

AMLX fundamentals

AMLX Q4 2025 Earnings

Earnings Call

You can ask Aime

AMLX

AMLX fundamentals

AMLX Q4 2025 Earnings

Earnings Call

AMLX Earnings Call Summary for Q4/20258:00 AM on Mar 3, 2026

AMLX Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

AMLX Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

AMLX Earnings Call Summary for Q1/20258:00 AM on May 8, 2025

AMLX Earnings Call Summary for Q4/20248:00 AM on Mar 4, 2025

You can ask Aime